Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Biotechnology Product for Wound Healing More
An active ingredient purified from herbal material for the treatment of skin disorders and for wound-healing. More
Stayzon's surgical prep product with Chlorhexidine is a unique 3 for 1 combination product. The mastic gum based product kills bacteria with Chlorhexidine, prevents bacterial migration, and allows drapes to stick better than other prep products. More
Indicated for the treatment and prevention of diabetic foot ulcers. More
Our passive immunity patent portfolio concerns the local or topical administration of monoclonal or polyclonal antibody compositions in the prevention and treatment of infectious disease. More
SmarBUCKL is produced with biocompatible and slow-resorbing biomaterials which will not induce immunoreactions and can be resorbed after implantation. The SmarBUCKL doesn't need to be exteriorized by a second operation after patient recovers. More
Vitamin C offered in 300mg doses More
Lip patch containing acyclovir for treamtent of Herpes labialis / cold sores More
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us